4D-710 — Regulatory decision
H2 2026
• Phase 2 ongoing, fully funded by the Cystic Fibrosis Foundation, with program update expected in H2 2026Source filing
FDMT biotech catalysts & pipeline
4D MOLECULAR THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
4D-150 — Full data
Q4 2026
SPECTRA clinical trial 2-year data expected in Q4 2026Source filing
4D-710 — Full data
Q4 2026
AEROW Phase 1/2 clinical trial and program update expected in Q4 2026Source filing
4D-150 — Topline data
Q2 2027
4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027Source filing
4D-150 — Topline data
H2 2027
Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027Source filing
4D-150 — Conference presentation
Q3 2026
• 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2 2026Source filing